Methodology of Clinical Trials

The EORTC New Drug Development Office (NDDO) was established in 1984 and remained active in the field of anticancer drug development for 15 years. Part 1 of our article describes how NDDO was set up under the EORTC umbrella as an infrastructure for drug development; this part describes NDDO’s main achievements during this period.

The EORTC New Drug Development Office (NDDO) was established in 1984 and remained active in the field of anticancer drug development for 15 years. This article provides overviews of new experimental anticancer agents which were investigated in various development phases, including pharmaceutical development, preclinical toxicology, bioassay development, preclinical pharmacokinetics, phase I dose escalation studies and disease-oriented phase II studies.

Brain tumours are among the cancers with the worst outlook and are hard to treat owing to factors such as inoperable locations in the brain and the difficulty of developing drugs that can cross the blood-brain barrier.

Chemotherapies are still essential to treat many cancer patients, and platinum-based drugs are among the most widely deployed. Successive generations of platinum agents are a European success story.

Chemotherapies are still essential to treat many cancer patients, and platinum-based drugs are among the most widely deployed. Successive generations of platinum agents are a European success story.

Chemotherapies are still essential to treat many cancer patients, and platinum-based drugs are among the most widely deployed. Successive generations of platinum agents are a European success story.